Cortex Pharmaceuticals, Valeant Pharmaceutical International Inc. deal

Cortex reacquired a portfolio of Ampakines for respiratory depression and related IP from Valeant. Valeant, which gained the assets through last year's merger with Biovail Corp., discontinued the Ampakine program last November after it did not fit with the merged company's strategic and financial focus (see BioCentury, April 5, 2010 & Nov. 8, 2010). ...